Formoterol Thrice Weekly Does Not Result in the Development of Tolerance to Bronchoprotection
BACKGROUND: Loss of bronchoprotection routinely follows regular treatment with beta2-agonists. There are no data on the effects on bronchoprotection for thrice weekly use of a beta2-agonist.
Saved in:
Main Authors: | Beth E Davis, John K Reid, Donald W Cockcroft |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2003-01-01
|
Series: | Canadian Respiratory Journal |
Online Access: | http://dx.doi.org/10.1155/2003/148740 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improvements of the integral Jensen inequality through the treatment of the concept of convexity of thrice differential functions
by: Asadullah Sohail, et al.
Published: (2024-12-01) -
Effect of a Single Dose Montelukast Sodium on Methacholine Chloride PC20
by: Beth E Davis, et al.
Published: (2005-01-01) -
Faster Onset of Bronchodilation with Formoterol than with Salmeterol in Patients with Stable, Moderate-Severe Copd: Results of a Randomized, Double-Blind Clinical Study
by: John Kottakis, et al.
Published: (2002-01-01) -
Seasonal Fluctuations in Airway Responsiveness in Elite Endurance Athletes
by: Howard B Hemingson, et al.
Published: (2004-01-01) -
Single inhaler with beclometasone, formoterol, and glycopyrronium versus triple therapies in adults with uncontrolled asthma: a systematic review and meta-analysis
by: Fulvio Braido, et al.
Published: (2025-02-01)